Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma

Abstract

Serum assay of anti-p53 antibodies is a rapid and readily facilitated test for predicting tumor advancement, depth of invasion, and liver metastasis, and it will show a poorer prognosis for surgically treated patients with gastric carcinoma.